Vaccine-associated hypersensitivity

      Information for Category 1 CME Credit

      Credit can now be obtained, free for a limited time, by reading the review articles in this issue. Please note the following instructions.
      Method of Physician Participation in Learning Process: The core material for these activities can be read in this issue of the Journal or online at the JACI Web site: www.jacionline.org. The accompanying tests may only be submitted online at www.jacionline.org. Fax or other copies will not be accepted.
      Date of Original Release: February 2018. Credit may be obtained for these courses until January 31, 2019.
      Copyright Statement: Copyright © 2018-2019. All rights reserved.
      Overall Purpose/Goal: To provide excellent reviews on key aspects of allergic disease to those who research, treat, or manage allergic disease.
      Target Audience: Physicians and researchers within the field of allergic disease.
      Accreditation/Provider Statements and Credit Designation: The American Academy of Allergy, Asthma & Immunology (AAAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The AAAAI designates this journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
      List of Design Committee Members: Michael M. McNeil, MD, MPH, and Frank DeStefano, MD, MPH (authors); Zuhair K. Ballas, MD (editor)
      Disclosure of Significant Relationships with Relevant Commercial
      Companies/Organizations: The authors declare that they have no relevant conflicts of interest. Z. K. Ballas (editor) disclosed no relevant financial relationships.
      Activity Objectives:
      • 1.
        To be able to discuss the differences in underlying mechanisms and presentation of immediate and delayed vaccine reactions.
      • 2.
        To be aware of the most recent vaccine guidelines regarding patients with egg allergy and influenza vaccination.
      • 3.
        To understand the limited data supporting other components of vaccines that might be implicated as possible causes of anaphylaxis.
      • 4.
        To be able to discuss the rate and clinical risk factors for vaccine-triggered anaphylaxis.
      Recognition of Commercial Support: This CME activity has not received external commercial support.
      List of CME Exam Authors: Daniel Har, MD, Shyam Joshi, MD, Mariam Wahidi, MD, Shazia Lutfeali, MD, and David A. Khan, MD.
      Disclosure of Significant Relationships with Relevant Commercial
      Companies/Organizations: The exam authors disclosed no relevant financial relationships.
      Vaccine-associated hypersensitivity reactions are not infrequent; however, serious acute-onset, presumably IgE-mediated or IgG and complement-mediated anaphylactic or serious delayed-onset T cell–mediated systemic reactions are considered extremely rare. Hypersensitivity can occur because of either the active vaccine component (antigen) or one of the other components. Postvaccination acute-onset hypersensitivity reactions include self-limited localized adverse events and, rarely, systemic reactions ranging from urticaria/angioedema to full-blown anaphylaxis with multisystem involvement. Risk of anaphylaxis after all vaccines is estimated to be 1.31 (95% CI, 0.90-1.84) per million vaccine doses, respectively. Serious hypersensitivity reactions after influenza vaccines are particularly important because of the large number of persons vaccinated annually. Influenza vaccines are unique in requiring annual changes in the vaccines’ antigenic composition to match the predicted circulating influenza strains. Recently, novel influenza vaccine types were introduced in the United States (recombinant vaccines, some with higher antigen content and a new adjuvanted vaccine). Providers should be aware of changing recommendations on the basis of recent published evidence for persons with a history of egg allergy to receive annual influenza vaccination. Further research is needed to elucidate the pathophysiology and risk factors for reported vaccine-associated adverse events. Further research is also needed to determine whether repeated annual inactivated influenza vaccination, the number of vaccine antigens administered at the same time, and the current timing of routine infant vaccinations are optimal for overall population well-being.

      Key words

      Abbreviations used:

      ACIP (Advisory Committee on Immunization Practices), Alpha-gal (Galactose-α-1,3-galactose), DTaP (Diphtheria, tetanus, and acellular pertussis vaccine), FDA (US Food and Drug Administration), HA (Hemagglutinin), MF59 (Oil-in-water emulsion of squalene adjuvant), MMR (Measles, mumps, and rubella vaccine), Tdap (Tetanus, reduced diphtheria, and acellular pertussis vaccine), TIV (Trivalent inactivated influenza vaccine), VAERS (Vaccine Adverse Event Reporting System), VSD (Vaccine Safety Datalink)
      To read this article in full you will need to make a payment

      References

        • National Vaccine Advisory Committee
        Protecting the public's health: critical functions of the Section 317 Immunization Program—a report of the National Vaccine Advisory Committee.
        Public Health Rep. 2013; 128: 78-95
        • Robinson C.L.
        • Romero J.R.
        • Kempe A.
        • Pellegrini C.
        Advisory Committee on Immunization Practices (ACIP) Child/Adolescent Immunization Work Group. Advisory Committee on Immunization Practices Recommended immunization schedule for children and adolescents aged 18 years or younger—United States, 2017.
        MMWR Morb Mortal Wkly Rep. 2017; 66: 134-135
        • Scarbrough Lefebvre C.D.
        • Terlinden A.
        • Standaert B.
        Dissecting the indirect effects caused by vaccines into the basic elements.
        Hum Vaccines Immunother. 2015; 11: 2142-2157
        • Caubet J.C.
        • Ponvert C.
        Vaccine allergy.
        Immunol Allergy Clin North Am. 2014; 34: 597-613
        • Dreskin S.C.
        • Halsey N.A.
        • Kelso J.M.
        • Wood R.A.
        • Hummell D.S.
        • Edwards K.M.
        • et al.
        International consensus (ICON): allergic reactions to vaccines.
        World Allergy J. 2016; 9: 32
        • Simons F.E.R.
        • Ebisawa M.
        • Sanchez-Borges M.
        • Thong B.Y.
        • Worm M.
        • Kase Tanno L.
        • et al.
        2015 update of the evidence base: World Allergy Organization anaphylaxis guidelines.
        World Allergy Organ J. 2015; 8: 32
        • Simons F.E.R.
        • Sampson H.A.
        Anaphylaxis: unique aspects of clinical diagnosis and management in infants (birth to age 2 years).
        J Allergy Clin Immunol. 2015; 135: 1125-1131
        • Lieberman P.
        • Nicklas R.A.
        • Randolph C.
        • Oppenheimer J.
        • Berstein D.
        • Bernstein J.
        • et al.
        Anaphylaxis–a practice parameter update 2015.
        Ann Allergy Asthma Immunol. 2015; 115: 341-384
        • Nilsson L.
        • Brockow K.
        • Alm J.
        • Cardona V.
        • Caubert J.C.
        • Gomes E.
        • et al.
        Vaccination and allergy: EAACI position paper, practical aspects.
        Pediatr Allergy Immunol. 2017; 28: 628-640
        • Zafack J.G.
        • De Serres G.
        • Rouleau I.
        • Gariépy M.C.
        • Gagnon R.
        • Drolet J.P.
        • et al.
        Clinical approach used in medical consultations for allergic-like events following immunization: case series report in relation to practice guidelines.
        J Allergy Clin Immunol. 2017; 5: 718-727
        • Radonjic-Hoesli S.
        • Hofmeier K.S.
        • Micaletto S.
        • Schmid-Grendelmeier P.
        • Bircher A.
        • Simon D.
        Urticaria and angioedema: an update on classification and pathogenesis.
        Clin Rev Allergy Immunol. 2017; ([Epub ahead of print])
        • Jaiganesh T.
        • Weise M.
        • Hollingsworth J.
        • Hughan C.
        • Kamara M.
        • Wood P.
        • et al.
        Acute angioedema: recognition and management in the emergency department.
        Eur J Emerg Med. 2013; 20: 10-17
        • Miliauskas J.R.
        • Mukherjee T.
        • Dixon B.
        Postimmunization (vaccination) injection-site reactions. A report of four cases and review of the literature.
        Am J Surg Pathol. 1993; 17: 516-524
        • Lauren C.T.
        • Belsito D.V.
        • Morel K.D.
        • LaRussa P.
        Case report of subcutaneous nodules and sterile abscesses due to delayed hypersensitivity to aluminum-containing vaccines.
        Pediatrics. 2016; 138: e20141690
      1. Stratton K. Ford A. Rusch E. Clayton E.W. Adverse effects of vaccines; evidence and causality. Institute of Medicine, National Academies Press, Washington (DC)2001
        • Echeverria-Zudaire L.A.
        • Ortigosa-del Castillo L.
        • Alonso-Lebrero E.
        • Álvarez-García F.J.
        • Cortés-Álvarez N.
        • García-Sánchez N.
        • et al.
        Consensus document on the approach to children with allergic reactions after vaccination or allergy to vaccine components.
        Allergol Immunopathol (Madr). 2015; 43: 304-325
        • Kelso J.M.
        Influenza vaccine and egg allergy: nearing the end of an evidence-based journey.
        J Allergy Clin Immunol. 2015; 3: 140-141
        • Grohskopf L.A.
        • Sokolow L.Z.
        • Broder K.R.
        • Walter E.B.
        • Bresee J.S.
        • Fry A.M.
        • et al.
        Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices—United States, 2017–18 Influenza Season.
        MMWR Recomm Rep. 2017; 66: 1-24
        • Committee on Infectious Diseases
        Recommendations for prevention and control of influenza in children, 2017-2018.
        Pediatrics. 2017; 140: e20172550
        • Kelso J.M.
        • Jones R.T.
        • Yunginger J.W.
        Anaphylaxis to measles, mumps, and rubella vaccine mediated by IgE to gelatin.
        J Allergy Clin Immunol. 1993; 91: 867-872
        • Pool V.
        • Braun M.M.
        • Kelso J.M.
        • Mootrey G.
        • Chen R.T.
        • Yunginger J.W.
        • et al.
        Prevalence of anti-gelatin IgE antibodies in people with anaphylaxis after measles-mumps rubella vaccine in the United States.
        Pediatrics. 2002; 110: e71
        • Commins S.P.
        • Satinover S.M.
        • Hosen J.
        • Mozena J.
        • Borish L.
        • Lewis B.D.
        • et al.
        Delayed anaphylaxis, angioedema, or urticaria after consumption of red meat in patients with IgE antibodies specific for galactose-alpha-1,3-galactose.
        J Allergy Clin Immunol. 2009; 123: 426-433
        • Stone C.A.
        • Hemler J.A.
        • Commins S.P.
        • Schuyler A.J.
        • Phillips E.J.
        • Peebles R.S.
        • et al.
        Anaphylaxis after zoster vaccine: Implicating alpha-gal allergy as a possible mechanism.
        J Allergy Clin Immunol. 2017; 139: 1710-1713.e2
        • DiMiceli L.
        • Pool V.
        • Kelso J.M.
        • Shadomy S.V.
        • Iskander J.
        • VAERS Team
        Vaccination of yeast sensitive individuals: review of safety data in the US Vaccine Adverse Event Reporting System (VAERS).
        Vaccine. 2006; 24: 703-707
        • Kattan J.D.
        • Konstantinou G.N.
        • Cox A.L.
        • Nowak-Węgrzyn A.
        • Gimenez G.
        • Sampson H.A.
        • et al.
        Anaphylaxis to diphtheria, tetanus, and pertussis vaccines among children with cow's milk allergy.
        J Allergy Clin Immunol. 2011; 128: 215-218
        • Bergfors E.
        • Trollfors B.
        Sixty-four children with persistent itching nodules and contact allergy to aluminium after vaccination with aluminium-adsorbed vaccines-prognosis and outcome after booster vaccination.
        Eur J Pediatr. 2013; 172: 171-177
        • Rouleaux I.
        • De Serres G.
        • Drolet J.P.
        • Skowronski D.M.
        • Ouakki M.
        • Toth E.
        • et al.
        Increased risk of anaphylaxis following administration of 2009 AS03-adjuvanted monovalent pandemic A/H1N1 (H1N1pdm09) vaccine.
        Vaccine. 2013; 31: 5989-5996
        • Rouleaux I.
        • De Serres G.
        • Skowronski D.M.
        • Drolet J.P.
        • Lemire C.
        • Toth E.
        • et al.
        Risk factors associated with anaphylaxis and other allergic-like events following receipt of 2009 monovalent AS03-adjuvanted pandemic influenza vaccine in Quebec, Canada.
        Vaccine. 2014; 32: 3480-3487
        • Grohskopf L.A.
        • Sokolow L.Z.
        • Broder K.R.
        • Olsen S.J.
        • Karron R.A.
        • Jernigan D.B.
        • et al.
        Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP)-United States, 2016-17 influenza season.
        MMWR Morb Mortal Wkly Recomm Rep. 2016; 65: 691-697
        • Tsai T.F.
        Fluad®-MF59®-Adjuvanted influenza vaccine in older adults.
        Infect Chemother. 2013; 45: 159-174
        • Pellegrini M.
        • Nicolay U.
        • Lindert K.
        • Groth N.
        • Della Cioppa G.
        MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database.
        Vaccine. 2009; 27: 6959-6965
      2. Cuhna JP. RxList FLUAD. Available at: http://www.rxlist.com/fluad-side-effects-drug-center.htm (date of last RxList review 7/3/2017). Accessed October 20, 2017.

      3. November 23, 2015 Summary basis for regulatory action–FLUAD. Available at: https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm473989.htm. Accessed December 12, 2017.

        • Centers for Disease Control and Prevention
        Hamborsky J. Kroger A. Wolfe S. Epidemiology and prevention of vaccine-preventable diseases. 13th ed. Public Health Foundation, Washington (DC)2015
        • Leventhal J.S.
        • Berger E.M.
        • Brauer J.A.
        • Cohen D.E.
        Hypersensitivity reactions to vaccine constituents: a case series and review of the literature.
        Dermatitis. 2012; 23: 102-109
      4. Kroger AT, Duchin J, Vázquez M. General best practice guidelines for immunization. Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP). Available at: www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf. Accessed December 12, 2017.

        • Vogt T.
        • Landthaler M.
        • Stolz W.
        Generalized eczema in an 18-month-old boy due to phenoxyethanol in DPT vaccine.
        Contact Dermatitis. 1998; 38: 50-51
        • Nagao M.
        • Fujisawa T.
        • Ihara T.
        • Kino Y.
        Highly increased levels of IgE antibodies to vaccine components in children with influenza vaccine–associated anaphylaxis.
        J Allergy Clin Immunol. 2016; 137: 861-867
        • Russell M.
        • Pool V.
        • Kelso J.M.
        • Tomazic-Jezic V.J.
        Vaccination of persons allergic to latex: a review of safety data in the Vaccine Adverse Event Reporting System (VAERS).
        Vaccine. 2004; 23: 664-667
        • Arroabarren E.
        • Anda M.
        • Sanz M.L.
        Anaphylaxis to pneumococcal vaccine; CRM(197): novel cause of vaccine allergy.
        Pediatr Allergy Immunol. 2016; 27: 425-437
        • Ruggeberg J.U.
        • Gold M.S.
        • Bayas J.M.
        • Blum M.D.
        • Bonhoeffer J.
        • Friedlander S.
        • et al.
        Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data.
        Vaccine. 2007; 25: 5675-5684
        • Sampson H.A.
        • Muñoz-Furlong A.
        • Bock S.A.
        • Schmitt C.
        • Bass R.
        • Chowdary B.A.
        • et al.
        Second symposium on the definition and management of anaphylaxis: summary report-second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network Symposium.
        J Allergy Clin Immunol. 2006; 117: 391-397
        • Bohlke K.
        • Davis R.L.
        • Marcy S.M.
        • Braun M.M.
        • DeStefano F.
        • Black S.B.
        • et al.
        Risk of anaphylaxis after vaccination of children and adolescents.
        Pediatrics. 2013; 112: 815-820
        • McNeil M.M.
        • Weintraub E.S.
        • Duffy J.
        • Sukumaran L.
        • Jacobsen S.J.
        • Klein N.P.
        • et al.
        Risk of anaphylaxis after vaccination in children and adults.
        J Allergy Clin Immunol. 2016; 137: 868-878
        • Brotherton J.M.
        • Gold M.S.
        • Kemp A.S.
        • McIntyre P.B.
        • Burgess M.A.
        • Campbell-Lloyd S.
        • et al.
        Anaphylaxis following quadrivalent human papillomavirus vaccination.
        CMAJ. 2008; 179: 525-533
        • Zhou W.
        • Pool V.
        • Iskander J.K.
        • English-Bullard R.
        • Ball R.
        • Wise R.P.
        • et al.
        Surveillance for safety after immunization: Vaccine Adverse Event Reporting Systemn (VAERS)—United States, 1991-2001.
        MMWR Surveill Summ. 2003; 52: 1-24
        • Kelso J.
        • Mootrey G.T.
        • Tsai T.F.
        Anaphylaxis from yellow fever vaccine.
        J Allergy Clin Immunol. 1999; 103: 698-701
        • Erlewyn-Lajeunesse M.
        • Hunt L.P.
        • Heath P.T.
        • Finn A.
        Anaphylaxis as an adverse event following immunization in the UK and Ireland.
        Arch Dis Child. 2012; 97: 487-490
        • Cheng D.R.
        • Perret K.P.
        • Choo S.
        • Danchin M.
        • Buttery J.P.
        • Crawford N.W.
        Pediatric anaphylactic adverse events following immunization in Victoria, Australia from 2007 to 2013.
        Vaccine. 2015; 33: 1602-1607
        • McNeil M.M.
        • Gee J.
        • Weintraub E.S.
        • Belongia E.A.
        • Lee G.M.
        • Glanz J.M.
        • et al.
        The Vaccine Safety Datalink: successes and challenges monitoring vaccine safety.
        Vaccine. 2014; 32: 5390-5398
        • Sargant N.
        • Erlewyn-Lajeunesse M.
        • Benger J.
        Does anaphylaxis masquerade as asthma in children?.
        Emerg Med. 2015; 32: 83-84
        • Tavares F.
        • Delaigle A.
        • Slavin D.
        • Bauchau V.
        • Fries L.
        • Siefert H.
        Anaphylaxis following H1N1 pandemic vaccines: safety data in perspective.
        Vaccine. 2011; 29: 6402-6407
        • Erlewyn-Lajeunesse M.
        • Dymond S.
        • Slade I.
        • Mansfield H.L.
        • Fish R.
        • Jones O.
        • et al.
        Diagnositic utility of two case definitions for anaphylaxis: a comparison using a retrospective case notes analysis in the UK.
        Drug Saf. 2010; 33: 57-64
        • González-Pérez A.
        • Aponte Z.
        • Vidaurre C.F.
        • Rodríguez L.A.
        Anaphylaxis epidemiology in patients with and patients without asthma: a United Kingdom database review.
        J Allergy Clin Immunol. 2010; 125: 1098-1104
        • Clark S.
        • Wei W.
        • Rudders S.A.
        • Camargo Jr., C.A.
        Risk factors for severe anaphylaxis in patients receiving anaphylaxis treatment in US emergency departments and hospitals.
        J Allergy Clin Immunol. 2014; 134: 1125-1130
        • Chen W.
        • Mempel M.
        • Schober W.
        • Behrendt H.
        • Ring J.
        Gender difference, sex hormones, and immediate type hypersensitivity reactions.
        Allergy. 2008; 63: 1418-1427
        • Decker W.W.
        • Campbell R.L.
        • Manivannan V.
        • Luke A.
        • St Sauver J.L.
        • Weaver A.
        • et al.
        The etiology and incidence of anaphylaxis in Rochester, Minnesota: a report from the Rochester Epidemiology Project.
        J Allergy Clin Immunol. 2008; 122: 1161-1165
        • Cook I.F.
        Sexual dimorphism of humoral immunity with human vaccines.
        Vaccine. 2008; 26: 3551-3555
        • Cook I.F.
        Sex differences in injection site reactions with human vaccines.
        Hum Vaccin. 2009; 5: 441-449
        • Klein S.L.
        • Jedlicka A.
        • Pekosz A.
        The Xs and Y of immune responses to viral vaccines.
        Lancet Infect Dis. 2010; 10: 338-349
        • Engler R.J.
        • Nelson M.R.
        • Klote M.M.
        • VanRaden M.J.
        • Huang C.Y.
        • Cox N.J.
        • et al.
        Half- vs full-dose trivalent inactivated influenza vaccine (2004-2005): age, dose, and sex effects on immune responses.
        Arch Intern Med. 2008; 168: 2405-2414
        • Nichol K.L.
        • Margolis K.L.
        • Lind A.
        • Murdoch M.
        • McFadden R.
        • Hauge M.
        • et al.
        Side effects associated with influenza vaccination in healthy working adults. A randomized, placebo-controlled trial.
        Arch Intern Med. 1996; 156: 1546-1550
        • Khalil M.K.
        • Al-Mazrou Y.Y.
        • Al-Ghamdi Y.S.
        • Tumsah S.
        • Al-Jeffri M.
        • Meshkhas A.
        Effect of gender on reporting of MMR adverse events in Saudi Arabia.
        East Mediterr Health J. 2003; 9: 152-158
        • Benjamin C.M.
        • Chew G.C.
        • Silman A.J.
        Joint and limb symptoms in children after immunisation with measles, mumps, and rubella vaccine.
        BMJ. 1992; 304: 1075-1078
        • Pennell L.M.
        • Galligan C.L.
        • Fish E.N.
        Sex affects immunity.
        J Autoimmun. 2012; 38: 282-291
        • Verthelyi D.
        Sex hormones as immunomodulators in health and disease.
        Int Immunopharmacol. 2001; 1: 983-993
        • Hox V.
        • Desai A.
        • Bandara G.
        • Gilfillan A.M.
        • Metcalfe D.D.
        • Olivera A.
        Estrogen increases the severity of anaphylaxis in female mice through enhanced endothelial nitric oxide synthase expression and nitric oxide production.
        J Allergy Clin Immunol. 2015; 135: 729-736
        • Bektas A.
        • Schurman S.H.
        • Sen R.
        • Ferrucci L.
        Human T cell immunosenescence and inflammation in aging.
        J Leukoc Biol. 2017; 102: 977-988
        • Vesikari T.
        • Pellegrini M.
        • Karvonen A.
        • Groth N.
        • Borkowski A.
        • O’Hagan D.T.
        • et al.
        Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant.
        Pediatr Infect Dis J. 2009; 28: 563-571
        • Nolan T.
        • Bravo L.
        • Ceballos A.
        • Mitha E.
        • Gray G.
        • Quiambao B.
        • et al.
        Enhanced and persistent antibody response against homologous and heterologous strains elicited by a MF59®-adjuvanted influenza vaccine in infants and young children.
        Vaccine. 2014; 32: 6146-6156
      5. An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI), Canadian Immunization Guide Chapter on Influenza and Statement on Seasonal Influenza Vaccine for 2015-2016. Public Health Agency of Canada, Ottawa, Ontario, Canada2015
        • Yang L.P.H.
        Recombinant trivalent influenza vaccine (Flublok®): a review of its use in the prevention of seasonal influenza in adults.
        Drugs. 2013; 73: 1357-1366
        • Woo E.J.
        • Moro P.L.
        • Cano M.
        • Jankoskyi C.
        Allergic reactions after egg-free recombinant influenza vaccine: reports of the US Vaccine Adverse Event Reporting System.
        Clin Infect Dis. 2015; 60: 777-780
        • Shimabukuro T.T.
        • Nguyen M.
        • Martin D.
        • DeStefano F.
        Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS).
        Vaccine. 2015; 33: 4398-4405
        • Glanz J.M.
        • Newcomer S.R.
        • Hambidge S.J.
        • Daley M.F.
        • Narwaney K.J.
        • Xu S.
        • et al.
        Safety of trivalent inactivated influenza vaccine in children aged 24 to 59 months in the Vaccine Safety Datalink.
        Arch Pediatr Adolesc Med. 2011; 165: 749-755
      6. Anonymous. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee.
        Lancet. 1998; 351: 1225-1232
        • Strachan D.P.
        Hay fever, hygiene, and household size.
        BMJ. 1989; 299: 1259-1260
        • Brooks C.
        • Pearce N.
        • Douwes J.
        The hygiene hypothesis in allergy and asthma: an update.
        Curr Opinion Allergy Clin Immunol. 2013; 13: 70-77
        • Romagnani S.
        The increased prevalence of allergy and the hygiene hypothesis: missing immune deviation, reduced immune suppression, or both?.
        Immunology. 2004; 112: 352-363
        • Stiemsma L.T.
        • Reynolds L.A.
        • Turvey S.E.
        • Finlay B.B.
        The hygiene hypothesis: current perspectives and future therapies.
        Immunotargets Ther. 2015; 4: 143-157
        • Kemp A.
        • Björksten K.A.
        Immune deviation and the hygiene hypothesis: a review of the epidemiological evidence.
        Pediatr Allergy Immunol. 2003; 14: 74-80
        • Keet C.A.
        • Savage J.H.
        • Seopaul S.
        • Peng R.D.
        • Wood R.A.
        • Matsui E.C.
        Temporal trends and racial/ethnic disparity in self-reported pediatric food allergy in the United States.
        Ann Allergy Asthma Immunol. 2014; 112: 222-229
        • Reynolds L.A.
        • Finlay B.B.
        Early life factors that affect allergy development.
        Nat Rev Immunol. 2017; 17: 518-528
        • Schlaud M.
        • Schmitz R.
        • Poethko-Mϋller C.
        • Kuhnert R.
        Vaccinations in the first year of life and risk of atopic disease—results from the KiGGS study.
        Vaccine. 2017; 35: 5156-5162
        • Kiraly N.
        • Koplin J.J.
        • Crawford N.W.
        • Bannister S.
        • Flanagan K.L.
        • Holt P.G.
        • et al.
        Timing of routine infant vaccinations and risk of food allergy and eczema at one year of age.
        Allergy. 2016; 71: 541-549